This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmology, and organ preservation. It highlights the rise of generative biology, featuring multimodal protein foundation models that jointly reason over sequence, structure, and function to design novel proteins, AI platforms for de novo protein and cyclic peptide design, and machine learning systems that engineer CRISPR gene-editing tools for therapeutic development. The edition showcases clinical genomics platforms that automate variant interpretation and reporting, long-read sequencing approaches that resolve epigenetic modifications, gene-expression-based molecular diagnostics for early cancer detection, and cerebrospinal fluid seed-amplification assays that detect pathological alpha-synuclein for earlier, biomarker-driven Parkinson's diagnosis. It further covers nucleic acid and targeted therapeutics, including antisense RNA candidates for chronic hepatitis B, first-in-class telomerase-inhibiting oligonucleotides for lower-risk myelodysplastic syndromes, antibody-conjugated lipid nanoparticles for tissue-specific RNA delivery, and universal platforms enabling intracellular delivery of macromolecular drugs.

• Which innovations in AI-led drug discovery, diagnostics, and therapeutic delivery are transforming treatment approaches across oncology, ophthalmology, and organ preservation?
• What role do next-generation immunotherapy and cryoprotection-based strategies play in advancing bladder cancer treatment and improving hepatocyte survival?
• Which growth prospects exist for genetic engineering, biomarkers, tissue engineering, synthetic biology, microbiome, and disease management?